SUBSCRIBE
SUBSCRIBE
News   Drug Development

Depomed, Inc. Announces Completion Of Phase I Clinical Trial With Gastroesophageal Reflux Disease Compound; Phase IIA Clinical Trial Planned

August 15, 2006 | 
1 min read

Depomed, Inc. (Nasdaq:DEPO) today announced that it has completed a Phase I clinical trial to evaluate the delivery and absorption of a compound currently used to treat gastroesophageal reflux disease (GERD).

Clinical research Phase I Phase II
MORE ON THIS TOPIC
Cardiovascular disease
Merck’s Winrevair Cuts Morbidity, Mortality Risk by Over 75% in Phase III PAH Study
April 1, 2025
 · 
2 min read
 · 
Tristan Manalac
Climb up, hand help businessman build ladder
Diabetes
Vertex Cuts Diabetes Asset, but Analysts Keen on Phase III Option
March 31, 2025
 · 
4 min read
 · 
Annalee Armstrong
World heart day. Sketch style human heart. Retro halftone hands reaching out to each other. Modern collage. Valentines day banner. Healthcare medical concept. Healthy lifestyle.
Cardiovascular disease
Lilly’s RNA Silencer Lowers Key Cardiovascular Biomarker by Almost 94%
March 31, 2025
 · 
2 min read
 · 
Tristan Manalac
Success roadmap journey, milestone or career path achievement, route or pathway to achieve goals, accomplishment, assessment or way to success, businessman look at achievement milestone to success.
GLP-1
Novo Paints Murky Cardio Picture for Semaglutide Franchise
March 31, 2025
 · 
2 min read
 · 
Tristan Manalac